.png){kind=icon}
.png){kind=icon}
Return
Chronic Myeloid Leukemia, Version 2.2021
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2020.0047.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 (t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.
Keywords:
CHRONIC MYELOGENOUS LEUKEMIA
TYROSINE-KINASE INHIBITORS
CHRONIC-PHASE CML
CLONAL CHROMOSOMAL-ABNORMALITIES
IN-SITU HYBRIDIZATION
PHILADELPHIA-NEGATIVE CELLS
PATIENTS RECEIVING IMATINIB
STANDARD-DOSE IMATINIB
SUBCUTANEOUS OMACETAXINE MEPESUCCINATE
PULMONARY ARTERIAL-HYPERTENSION
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations